Zobrazeno 1 - 10
of 91
pro vyhledávání: ''
Autor:
Amy Zhang, Grainne M. O'Kane, Paz Polak, Celia M. T. Greenwood, James Joseph Biagi, Sandra Fischer, Julie M. Wilson, Louis-Martin Boucher, Gun Ho Jang, Zu-Hua Gao, Jennifer J. Knox, Yifan Wang, Yasser Riazalhosseini, Nathaniel Bouganim, Ayelet Borgida, David Valenti, Robert C. Grant, Steven Gallinger, Mehdi Masoomian, Robert E. Denroche, William D. Foulkes, John M. S. Bartlett, Chani Stossel, Maria Raitses-Gurevich, Alain Pacis, Ilinca Lungu, Talia Golan, Simeng Bu, Jean Monlong, T. Cabrera, George Zogopoulos, Celine Domecq, Spring Holter, Jin Yong Patrick Park, Jamil Asselah, Adeline Cuggia
Publikováno v:
WAng, Y, Patrick Park, J Y, Pacis, A, E. Denroche, R, Jang, G H, Zhang, A, Cuggia, A, Domecq, C, Monlong, J, Raitses-Gurevich, M, C. Grant, R, Borgida, A, Holter, S, Stossel, C, Bu, S, Masoomian, M, Lungu, I, Bartlett, J, M. Wilson, J, Gao, Z-H, Riazalhosseini, Y, Asselah, J, Bouganim, N, Cabrera, T, Boucher, L-M, Valenti, D, Biagi, J, M.T Greenwood, C, Polak, P, D. Foulkes, W, Golan, T, M. O'Kane, G, E. Fischer, S, J. Knox, J, Gallinger, S & Zogopoulos, G 2020, ' A preclinical trial and molecularly-annotated patient cohort identify predictive biomarkers in homologous recombination deficient pancreatic cancer ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-20-1439
Purpose:Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is
Autor:
Serguei Kozlov, Ming Yi, Suman Mukhopadhyay, William E. Burgan, Dwight V. Nissley, Debanjan Goswami, Pavan P. Adiseshaiah, Frank McCormick, Theresa Guerin
Publikováno v:
Cancer research, vol 80, iss 8
Pancreatic cancer is a disease with limited therapeutic options. Resistance to chemotherapies poses a significant clinical challenge for patients with pancreatic cancer and contributes to a high rate of recurrence. Oncogenic KRAS, a critical driver o
Autor:
Rebecca Boiarsky, Kevin S. Kapner, Daniel Zhao, Stephanie W. Cheng, Ananya D. Jambhale, Jimmy A. Guo, Patrick Z. Yu, Tyler Jacks, François Aguet, Daniel Y. Kim, Harshabad Singh, Hannah I. Hoffman, Brenton R. Paolella, Maryann Zhao, William L. Hwang, Steven I. Wang, Andrew J. Aguirre, John M. Krill-Burger, Westley W. Wu, Kristen E. Lowder, James M. McFarland, Tobiloba E. Oni, Aviv Regev, Gad Getz, Peter Chen, Scott P. Ginebaugh
Publikováno v:
Cancer Research. 81:PR-006
Targeted therapies for molecularly-defined subtypes have led to immense clinical benefit for many cancer types but have generally not been successful for pancreatic cancer. Given that the mainstay of treatment remains multi-agent chemotherapy with FO
Autor:
Raghu Kalluri, Chanjuan Shi, Valerie M. Weaver, Anna Chytil, Harold L. Moses, Fei Ye, Philip Owens, Sergey V. Novitskiy, Michael W. Pickup, Agnieszka E. Gorska
Publikováno v:
Cancer immunology research, vol 5, iss 9
The survival rate for pancreatic ductal adenocarcinoma (PDAC) remains low. More therapeutic options to treat this disease are needed, for the current standard of care is ineffective. Using an animal model of aggressive PDAC (Kras/p48TGFβRIIKO), we d
Publikováno v:
Cancer Research. 81:1323-1323
In this study, we develop a novel autophagy inhibitor targeting one of the most aggressive cell populations present in pancreatic tumors, the pancreatic cancer stem cell (CSC). Targeting this population which has the malignant properties of tumorigen
Autor:
Ashenafi Bulle
Publikováno v:
Cancer Research. 81:1086-1086
Background: Oncogenic KRAS is present in almost all cases of pancreatic ductal adenocarcinoma (PDAC). The mitogen-activated protein kinase (MAPK) pathway is the most cardinal signaling cascade utilized by KRAS, but targeting RAF or MEK, the key signa
Autor:
Allan J.W. Lui, Shawn M. Leland, Marc Ladanyi, Igor Odintsov, Romel Somwar, Morana Vojnic, Paul R. Bloom
Publikováno v:
Cancer Research. 81:935-935
Background. Oncogenic rearrangements of the neuregulin 1 gene (NRG1) consist of a 5' partner fused to a 3' NRG1 sequence that retains the EGF-like domain, and are found in 0.2% of solid tumors including lung, breast and gastrointestinal (GI) cancers.
Publikováno v:
Cancer Research. 80:694-694
Today, pancreatic cancer (PC) remains a major health problem in the US and soon will be the second most common cause of mortality due to cancer. However, most of the front-line PC chemotherapies cause serious side effects and a majority of patients w
Autor:
Saravanakumar Marimuthu, Imayavaramban Lakshmanan, Sakthivel Muniyan, Maneesh Jain, Surinder K. Batra, Moorthy P. Ponnusamy, Pranita Atri
Publikováno v:
Cancer Research. 80:6072-6072
Pancreatic cancer (PC) is one of the most lethal malignant tumors. Several membrane-bound mucins are overexpressed in PC, including MUC16. The role and molecular mechanism of MUC16 mucin, particularly carboxyl-terminal domain (MUC16-Cter) in metastas
Autor:
Tara N. Fujimoto, Meifang Yu, Yanqing Huang, Nicholas D. Nguyen, Cullen M. Taniguchi, Abagail M. Delahoussaye, Manuel A. Estrada
Publikováno v:
Cancer Research. 80:555-555
Background: Pancreatic ductal adenocarcinoma (PDAC) is driven by activating Kras mutations which cause a fragmented mitochondrial phenotype. We recently demonstrated that leflunomide, an FDA-approved drug for rheumatoid arthritis, could be repurposed